WILLIAM A contact WEISS

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
    Joachim Silber
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Med 6:14. 2008
  2. ncbi request reprint Can mouse models for brain tumors inform treatment in pediatric patients?
    William A Weiss
    Departments of Neurology, Pediatrics, and Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Semin Cancer Biol 14:71-7. 2004
  3. pmc Recognizing and exploiting differences between RNAi and small-molecule inhibitors
    William A Weiss
    University of California, 533 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Chem Biol 3:739-44. 2007
  4. ncbi request reprint Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma
    W A Weiss
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Cancer Res 60:2483-7. 2000
  5. ncbi request reprint Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum
    William A Weiss
    Department of Neurology, University of California, 521 Parnassus Avenue, San Francisco, California, CA 94143 0114, USA
    Oncogene 21:7453-63. 2002
  6. ncbi request reprint Genetics of brain tumors
    W A Weiss
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Curr Opin Pediatr 12:543-8. 2000
  7. ncbi request reprint Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, California 94143 0663, USA
    Cancer Res 63:8930-8. 2003
  8. ncbi request reprint Genetic determinants of malignancy in a mouse model for oligodendroglioma
    William A Weiss
    Department of Neurology, University of California, San Francisco, California 94143 0663, USA
    Cancer Res 63:1589-95. 2003
  9. pmc EGFR signals to mTOR through PKC and independently of Akt in glioma
    Qi Wen Fan
    Department of Neurology, University of California, 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Sci Signal 2:ra4. 2009
  10. ncbi request reprint RNA interference against a glioma-derived allele of EGFR induces blockade at G2M
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, CA 94143 0663, USA
    Oncogene 24:829-37. 2005

Research Grants

  1. Murine neuroblastoma models for preclinical therapeutics
    William Weiss; Fiscal Year: 2007
  2. Murine neuroblastoma models for preclinical therapeutics
    William A Weiss; Fiscal Year: 2010
  3. Medulloblastoma and Metastases
    WILLIAM A contact WEISS; Fiscal Year: 2010
  4. Mycn and Medulloblastoma
    William A Weiss; Fiscal Year: 2010
  5. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2010
  6. Imaging Kinase Activity In Vivo
    William Weiss; Fiscal Year: 2006
  7. Murine neuroblastoma models for preclinical therapeutics
    William Weiss; Fiscal Year: 2005
  8. GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA
    William Weiss; Fiscal Year: 2004
  9. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2011

Collaborators

Detail Information

Publications36

  1. pmc miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
    Joachim Silber
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Med 6:14. 2008
    ..In this study, we investigated the role of microRNAs in regulating the differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells...
  2. ncbi request reprint Can mouse models for brain tumors inform treatment in pediatric patients?
    William A Weiss
    Departments of Neurology, Pediatrics, and Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Semin Cancer Biol 14:71-7. 2004
    ..Mouse models for brain tumors may help to identify targeted agents, and combinations of agents, effective against these tumors. Such data can be used to prioritize therapies for clinical trials in children with these tumors...
  3. pmc Recognizing and exploiting differences between RNAi and small-molecule inhibitors
    William A Weiss
    University of California, 533 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Chem Biol 3:739-44. 2007
  4. ncbi request reprint Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma
    W A Weiss
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Cancer Res 60:2483-7. 2000
    ....
  5. ncbi request reprint Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum
    William A Weiss
    Department of Neurology, University of California, 521 Parnassus Avenue, San Francisco, California, CA 94143 0114, USA
    Oncogene 21:7453-63. 2002
    ..Recommendations were also made for preclinical validation of these models in cancer therapeutics, and for incorporation of surrogate markers of tumor burden to facilitate preclinical evaluation of new therapies...
  6. ncbi request reprint Genetics of brain tumors
    W A Weiss
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Curr Opin Pediatr 12:543-8. 2000
    ..Further studies are needed to identify genetic alterations in pilocytic and low-grade astrocytomas, which account for 40% of brain tumors in children...
  7. ncbi request reprint Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, California 94143 0663, USA
    Cancer Res 63:8930-8. 2003
    ..Our experiments provide a preclinical mechanistic basis for combining biologically based therapies directed against two targets within a complex signaling cascade...
  8. ncbi request reprint Genetic determinants of malignancy in a mouse model for oligodendroglioma
    William A Weiss
    Department of Neurology, University of California, San Francisco, California 94143 0663, USA
    Cancer Res 63:1589-95. 2003
    ..These models hold promise for studying tumor lineage, identifying contributing genetic alterations and evaluating preclinical therapies in this important neoplasm...
  9. pmc EGFR signals to mTOR through PKC and independently of Akt in glioma
    Qi Wen Fan
    Department of Neurology, University of California, 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Sci Signal 2:ra4. 2009
    ..These findings underline the importance of signaling between EGFR and mTOR in glioma, identify PKCalpha as essential to this network, and question the necessity of Akt as a critical intermediate coupling EGFR and mTOR in glioma...
  10. ncbi request reprint RNA interference against a glioma-derived allele of EGFR induces blockade at G2M
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, CA 94143 0663, USA
    Oncogene 24:829-37. 2005
    ....
  11. pmc Pleiotropic role for MYCN in medulloblastoma
    Fredrik J Swartling
    University of California at San Francisco, San Francisco, California 94158, USA
    Genes Dev 24:1059-72. 2010
    ..Targeted expression of MYCN thus contributes to initiation, progression, and maintenance of MB, suggesting a central role for MYCN in pathogenesis...
  12. ncbi request reprint Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8
    Chibo Hong
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, California 94143 0875, USA
    Cancer Res 65:3617-23. 2005
    ..The shared epigenetic inactivation of mSLC5A8 in mouse gliomas indicates an additional degree of commonality in the origin and/or pathway to tumorigenesis between primary human tumors and these mouse models of gliomas...
  13. doi request reprint The side story of stem-like glioma cells
    Anders I Persson
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
    Cell Stem Cell 4:191-2. 2009
    ..Surprisingly, temozolomide, the first-line chemotherapeutic used for treatment of glioma, increased this side population, and even more so when PTEN was deleted...
  14. pmc PI3K signaling in glioma--animal models and therapeutic challenges
    Christine K Cheng
    Department of Neurology, University of California, San Francisco, CA 94143, USA
    Brain Pathol 19:112-20. 2009
    ..The engagement of other survival pathways in response to PI3K inhibition prompts the need to develop combination therapies that promote cytotoxicity in cancer cells...
  15. pmc Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity
    Wei Yu
    Department of Anatomy, Neurology, University of California, San Francisco, California 94143, USA
    EMBO Rep 9:923-9. 2008
    ..These results might be relevant to the hyperactivation of RhoA and disruption of normal polarity frequently observed in human epithelial cancers...
  16. pmc A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma
    Qi Wen Fan
    Department of Neurology and Brain Tumor Research Center, Comprehensive Cancer Center, Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA
    Cancer Res 67:7960-5. 2007
    ..These experiments show that a dual inhibitor of PI3Kalpha and mTOR augments the activity of EGFR blockade, offering a mechanistic rationale for targeting EGFR, PI3Kalpha, and mTOR in the treatment of EGFR-driven, PTEN-mutant glioma...
  17. ncbi request reprint Isoform specific inhibitors of PI3 kinase in glioma
    Qi Wen Fan
    Department of Neurology, Pediatrics, Neurological Surgery, and Brain Tumor Research Center, Comprehensive Cancer Center, San Francisco, California 94143, USA
    Cell Cycle 5:2301-5. 2006
    ..This result suggests a potentially effective strategy for cancer therapy based on dual inhibition of these two PI3K family members...
  18. ncbi request reprint Childhood tumors of the nervous system as disorders of normal development
    Matthew R Grimmer
    Department of Neurology, University of California, San Francisco, CA 94143, USA
    Curr Opin Pediatr 18:634-8. 2006
    ..We provide a detailed discussion of two pediatric neural tumors, medulloblastoma and neuroblastoma, addressing tumorigenic causality and similarities within a pharmacological context...
  19. pmc A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 9:341-9. 2006
    ..PI-103 showed significant activity in xenografted tumors with no observable toxicity. These data demonstrate an emergent efficacy due to combinatorial inhibition of mTOR and PI3 kinase alpha in malignant glioma...
  20. pmc Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
    Louis Chesler
    Department of Neurology, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Res 66:8139-46. 2006
    ....
  21. pmc Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery
    Dennis J Yoon
    Department of Bioengineering, University of California, Los Angeles, CA 90095, USA
    Cancer Res 70:4520-7. 2010
    ..Treatment of GBM xenografts with mutant Tf-conjugated DT resulted in pronounced regression in vivo, indicating their potential use as drug carriers...
  22. pmc Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction
    Louis Chesler
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    Neoplasia 10:1268-74. 2008
    ....
  23. ncbi request reprint Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors
    Christopher S Hackett
    Department of Neurology, University of California, San Francisco, California 94143 0114, USA
    Cancer Res 63:5266-73. 2003
    ..These data demonstrate conservation of many genetic changes in murine and human neuroblastoma and suggest that further delineation of genetic abnormalities in murine tumors may identify genes important in human disease...
  24. ncbi request reprint Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling
    Qi Wen Fan
    Department of Neurology, University of California, San Francisco, CA 94143, USA
    Curr Biol 12:1386-94. 2002
    ..Because it is implicated in a large number of malignancies, EGFR provides an attractive target for such selective kinase inhibition...
  25. pmc Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma
    Louis Chesler
    Department of Pediatrics, Neurology, University of California San Francisco Medical School, San Francisco, California 94143, USA
    Cancer Res 67:9435-42. 2007
    ....
  26. pmc Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells
    Gary E Meyer
    Department of Pediatrics, University of California, San Francisco, California 94143, USA
    J Cell Biochem 102:1529-41. 2007
    ..In addition, NDGA inhibits the growth of xenografted human neuroblastoma tumors in nude mice. These results indicate that NDGA may be useful in the treatment of neuroblastoma and may function in part via disruption of IGF-IR signaling...
  27. ncbi request reprint Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
    Jimmy A Blair
    Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, USA
    Nat Chem Biol 3:229-38. 2007
    ....
  28. pmc A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
    Zachary A Knight
    Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA
    Cell 125:733-47. 2006
    ..These results illustrate systematic target validation using a matrix of inhibitors that span a protein family...
  29. ncbi request reprint Chemical genetic approaches to the development of cancer therapeutics
    Qi Wen Fan
    Department of Neurology, 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Opin Genet Dev 16:85-91. 2006
    ..Elucidation of the mechanisms through which specific small molecule drug-like agents impact crucial cancer pathways should yield important and clinically translatable insights into the use of similar agents in patients...
  30. ncbi request reprint Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3
    Tsui Ting Ching
    The Brain Tumor Research Center, Department of Neurological Surgery and the Biomedical Sciences Program, University of California San Francisco, San Franciso, California 94143, USA
    Nat Genet 37:645-51. 2005
    ..Defects in SHANK3 seem to underlie human 22q13 deletion syndrome. Furthermore, these patterns for SHANK3 are conserved in mice and rats...
  31. pmc BMPs oppose Math1 in cerebellar development and in medulloblastoma
    Matthew R Grimmer
    Department of Neurology, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 22:693-9. 2008
  32. ncbi request reprint Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma
    Catherine A Burkhart
    Children s Cancer Institute Australia for Medical Research, Sydney, Australia
    J Natl Cancer Inst 95:1394-403. 2003
    ..We used hMYCN antisense (AS) oligonucleotides to investigate, both in vitro and in vivo, the therapeutic potential of inhibiting hMYCN expression...
  33. pmc Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma
    Andy J Cheng
    Children s Cancer Institute Australia for Medical Research, P O Box 81, Randwick, 2031 Sydney, Australia
    Eur J Cancer 43:1467-75. 2007
    ..These isogenic lines together with the transgenic mice thus represent valuable models for investigating the biological characteristics of aggressive neuroblastoma...
  34. ncbi request reprint Brain tumors in S100beta-v-erbB transgenic rats
    Hiroko Ohgaki
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Neuropathol Exp Neurol 65:1111-7. 2006
    ....
  35. ncbi request reprint Genotype-phenotype correlations in tuberous sclerosis: who and how to treat
    Suzanne Goh
    Ann Neurol 60:505-7. 2006
  36. pmc Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification
    Loen M Hansford
    Children s Cancer Institute Australia for Medical Research, Randwick 2031, Australia
    Proc Natl Acad Sci U S A 101:12664-9. 2004
    ..Our studies provide a model for studying perinatal factors influencing embryonal tumor initiation...

Research Grants15

  1. Murine neuroblastoma models for preclinical therapeutics
    William Weiss; Fiscal Year: 2007
    ..Aim 3 evaluates a role for MYCN in maintaining angiogenesis in murine neuroblastoma, determines how therapies that disrupt Mycn impact this process, and evaluates the importance of p53 in effectiveness of anti-angiogenic therapies. ..
  2. Murine neuroblastoma models for preclinical therapeutics
    William A Weiss; Fiscal Year: 2010
    ..Aim 3 evaluates a role for MYCN in maintaining angiogenesis in murine neuroblastoma, determines how therapies that disrupt Mycn impact this process, and evaluates the importance of p53 in effectiveness of anti-angiogenic therapies. ..
  3. Medulloblastoma and Metastases
    WILLIAM A contact WEISS; Fiscal Year: 2010
    ..Successful completion of this proposal identifies metastases genes and new therapeutic targets for children with metastatic MB. ..
  4. Mycn and Medulloblastoma
    William A Weiss; Fiscal Year: 2010
    ..This study will clarify the importance of Mycn as a therapeutic target in medulloblastoma, and will evaluate a Mycn inhibitor that could potentially be translated to children with this important tumor. ..
  5. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2010
    ..Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets. ..
  6. Imaging Kinase Activity In Vivo
    William Weiss; Fiscal Year: 2006
    ....
  7. Murine neuroblastoma models for preclinical therapeutics
    William Weiss; Fiscal Year: 2005
    ..Successful completion of this aim should lead to an efficient mechanism to better characterize mechanisms, and to ascertain the preclinical efficacy of combination and continuous low dose therapies. ..
  8. GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA
    William Weiss; Fiscal Year: 2004
    ..Given the poor outcome associated with childhood neuroblastoma, this work has the potential to increase our understanding of the pathogenesis of neuroblastoma, and may result in improved therapies for children with this disorder. ..
  9. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2011
    ..Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets. ..